The stock of Horizon Pharma PLC (NASDAQ:HZNP) is a huge mover today! The stock increased 3.53% or $0.64 during the last trading session, hitting $18.77. About 2.23 million shares traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has risen 5.65% since February 29, 2016 and is uptrending. It has underperformed by 6.56% the S&P500.
The move comes after 9 months positive chart setup for the $2.92B company. It was reported on Oct, 4 by Barchart.com. We have $30.22 PT which if reached, will make NASDAQ:HZNP worth $1.78B more.
Analysts await Horizon Pharma PLC (NASDAQ:HZNP) to report earnings on November, 4. They expect $0.67 EPS, up 13.56% or $0.08 from last year’s $0.59 per share. HZNP’s profit will be $104.23 million for 7.00 P/E if the $0.67 EPS becomes a reality. After $0.42 actual EPS reported by Horizon Pharma PLC for the previous quarter, Wall Street now forecasts 59.52% EPS growth.
Horizon Pharma PLC (NASDAQ:HZNP) Ratings Coverage
Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Horizon Pharma has been the topic of 18 analyst reports since September 9, 2015 according to StockzIntelligence Inc. As per Tuesday, January 19, the company rating was initiated by Jefferies. The stock of Horizon Pharma PLC (NASDAQ:HZNP) has “Equal-Weight” rating given on Monday, July 11 by Morgan Stanley. Mizuho maintained Horizon Pharma PLC (NASDAQ:HZNP) rating on Tuesday, September 13. Mizuho has “Buy” rating and $33 price target. As per Thursday, December 3, the company rating was reinitiated by Morgan Stanley. Mizuho maintained it with “Buy” rating and $24 target price in Tuesday, May 10 report. The firm has “Buy” rating given on Tuesday, November 10 by Mizuho. JMP Securities reinitiated the shares of HZNP in a report on Wednesday, September 9 with “Mkt Outperform” rating. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Buy” rating by Mizuho on Tuesday, May 3. On Friday, September 16 the stock rating was downgraded by Cowen & Co to “Market Perform”. Jefferies reinitiated Horizon Pharma PLC (NASDAQ:HZNP) on Monday, November 23 with “Buy” rating.
According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNEÂ® (interferon gamma-1b), DUEXISÂ® (ibuprofen/famotidine), PENNSAIDÂ® (diclofenac sodium topical solution) 2% w/w, RAYOSÂ® (prednisone) delayed-release tablets and VIMOVOÂ® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment increased to 1.21 in Q2 2016. Its up 0.21, from 1 in 2016Q1. The ratio increased, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.
Moreover, California State Teachers Retirement System has 0.01% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 338,833 shares. Rothschild Asset Mgmt Incorporated holds 517,300 shares or 0.15% of its portfolio. Goldman Sachs Grp Inc Inc reported 232,656 shares or 0% of all its holdings. Global X Mgmt Ltd Liability accumulated 107,716 shares or 0.09% of the stock. Morgan Stanley holds 704,914 shares or 0% of its portfolio. Citadel Ltd Limited Liability Company owns 88,064 shares or 0% of their US portfolio. Nationwide Fund Advisors holds 0.01% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 105,655 shares. Profund Limited Liability Company holds 0.01% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 11,752 shares. Ladenburg Thalmann Service Incorporated accumulated 0.01% or 24,416 shares. Prtn Ltd accumulated 315,800 shares or 0.41% of the stock. Franklin Street Advsrs Nc holds 40,000 shares or 0.13% of its portfolio. The Germany-based Deutsche Commercial Bank Ag has invested 0.01% in Horizon Pharma PLC (NASDAQ:HZNP). The New York-based New York State Common Retirement Fund has invested 0.01% in Horizon Pharma PLC (NASDAQ:HZNP). Blackrock Investment Mngmt Limited last reported 600,780 shares in the company. American Interest Gp accumulated 92,884 shares or 0% of the stock.
Insider Transactions: Since June 15, 2016, the stock had 0 insider purchases, and 2 selling transactions for $500,280 net activity. Shares for $442,280 were sold by Nohria Virinder. SHERMAN JEFFREY W sold $58,000 worth of Horizon Pharma PLC (NASDAQ:HZNP) on Tuesday, August 2.
More important recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Globenewswire.com which released: “Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in …” on September 12, 2016, also Seekingalpha.com published article titled: “Horizon Pharma: Another Core Plus Biotech Worth Buying”, Marketwatch.com published: “Horizon Pharma to pay 21% premium to buy Raptor Pharmaceutical” on September 12, 2016. More interesting news about Horizon Pharma PLC (NASDAQ:HZNP) was released by: Moodys.com and their article: “Moody’s: Horizon’s Raptor acquisition credit negative” with publication date: September 12, 2016.
HZNP Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.